Top Markets
#1 Ontology Gas Ontology Gas +40.10%
#2 Verus Coin Verus Coin +22.50%
#3 EXOD EXOD +22.08%
#4 Status Status +19.99%
#5 Geodnet Geodnet +14.90%
#6 ETHGas ETHGas +13.90%
#7 The Black Bull The Black Bull +12.16%
#8 Fake World Assets Fake World Assets +11.14%
#9 Curve DAO Curve DAO +10.88%
#10 Pons Pons +10.54%
Coin of the day
Ontology Gas Ontology Gas
Settings
Language
ENGLISH
Currency
USD
Theme
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Rank in Stocks #25521
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Share Price
$9.81
Last synced: 2025-03-18
Market Cap
$48.68M
Change (1 day)
1.55%
Change (1 year)
0.00%
Country
US
Trade AlloVir, Inc. (ALVR)

Category

Healthcare
P/E ratio for AlloVir, Inc. (ALVR)
P/E ratio as of August 2026 TTM: -2.02
According to AlloVir, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.02. At the end of 2023 the company had a P/E ratio of 0.00.
P/E ratio history for AlloVir, Inc. from 2022 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -2.02 158.95%
2024 -0.78 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -1,545.70%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -1,615.95%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -1,707.13%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 292.85%
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.